Выявление факторов, препятствующих успешной HER-таргетной терапии при раке молочной железы и разработка противоопухолевого препарата, связывающего HER-лиганды

6 Января 2018 года — 31 Декабря 2020 года

Буздин А.А. (рук.)

Группа геномного анализа сигнальных систем клетки

Грант, РНФ

Список публикаций по проекту

  1. Sorokin M, Ignatev K, Barbara V, Vladimirova U, Muraveva A, Suntsova M, Gaifullin N, Vorotnikov I, Kamashev D, Bondarenko A, Baranova M, Poddubskaya E, Buzdin A (2020). Molecular Pathway Activation Markers Are Associated with Efficacy of Trastuzumab Therapy in Metastatic HER2-Positive Breast Cancer Better than Individual Gene Expression Levels. Biochemistry (Mosc) 85 (7), 758–772
  2. Sorokin M, Ignatev K, Poddubskaya E, Vladimirova U, Gaifullin N, Lantsov D, Garazha A, Allina D, Suntsova M, Barbara V, Buzdin A (2020). RNA Sequencing in Comparison to Immunohistochemistry for Measuring Cancer Biomarkers in Breast Cancer and Lung Cancer Specimens. Biomedicines 8 (5),
  3. (книга) Nikitin D, Sorokin M, Tkachev V, Garazha A, Markov A, Buzdin A (2019). RetroSpect, a new method of measuring gene regulatory evolution rates using co-mapping of genomic functional features with transposable elements. Evolution, Origin of Life, Concepts and Methods 42 (1), 85–111
  4. Borisov N, Sorokin M, Tkachev V, Garazha A, Buzdin A (2020). Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments. BMC Med Genomics 13 (Suppl 8), 111
  5. Sorokin M, Poddubskaya E, Baranova M, Glusker A, Kogoniya L, Markarova E, Allina D, Suntsova M, Tkachev V, Garazha A, Sekacheva M, Buzdin A (2020). RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol Case Stud 6 (2),
  6. Buzdin A, Skvortsova II, Li X, Wang Y (2021). Editorial: Next Generation Sequencing Based Diagnostic Approaches in Clinical Oncology. Front Oncol 10, 635555
  7. Kamashev D, Sorokin M, Kochergina I, Drobyshev A, Vladimirova U, Zolotovskaia M, Vorotnikov I, Shaban N, Raevskiy M, Kuzmin D, Buzdin A (2021). Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth. Heliyon 7 (3), e06394
  8. Raevskiy M, Sorokin M, Vladimirova U, Suntsova M, Efimov V, Garazha A, Drobyshev A, Moisseev A, Rumiantsev P, Li X, Buzdin A (2021). EGFR Pathway-Based Gene Signatures of Druggable Gene Mutations in Melanoma, Breast, Lung, and Thyroid Cancers. Biochemistry (Mosc) 86 (11), 1477–1488
  9. Lebedev TD, Khabusheva ER, Mareeva SR, Ivanenko KA, Morozov AV, Spirin PV, Rubtsov PM, Snezhkina AV, Kudryavtseva AV, Sorokin MI, Buzdin AA, Prassolov VS (2022). Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. J Biol Chem 298 (8), 102226
  10. Kamashev D, Shaban N, Suntsova M, Raevskiy M, Efimov V, Moisseev A, Sorokin M, Buzdin A (2022). Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition. Biomedicines 10 (8),